The health outcomes of psychedelics use survey (POCUS): a nationally representative survey study
Active Grant Awarded Last action
- Award ID
- R01DA061818
- Recipient
-
Regents Of The University Of Michigan UEI GNJ7BBP73WE9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $726,696
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 10% complete
- Place of performance
- Michigan, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, awarded Regents of the University of Michigan $726,696 on May 25, 2026, under Grant R01DA061818 in Assistance Listing 93.279, Drug Use and Addiction Research Programs. The award funds the Health Outcomes of Psychedelics Use Survey (POCUS), a nationally representative survey study that characterizes national perceptions of risks and safety, use patterns, and safety outcomes associated with psychedelics. The survey tests hypotheses on how policy changes affect use patterns and substance sourcing. The program supports basic, clinical, translational, and implementation research on substance use. Place of performance is Michigan, USA, and the ultimate completion date is March 31, 2031.
The Research Foundation for the State University of New York, doing business as Sponsored Projects Services, holds sub-award R01DA061818-SUBK00027501, dated September 21, 2026. Under that sub-award, Daniel Kruger at SUNY Buffalo, serving as multiple principal investigator, helps oversee survey development, piloting, and testing with NORC, and coordinates communication between the analytic team and manuscript writing personnel. Legacy Emanuel Hospital & Health Center holds sub-award R01DA061818-SUBK00027494, dated August 27, 2026. Under that sub-award, Dr. Wilson-Poe, serving as project PI, contributes to survey content, data analysis and interpretation, project administration, coordination with NORC as the data collection partner, regulatory responsibilities, data integrity, and dissemination.
Description
- Abstract
- The use of psychedelics such as psilocybin-containing mushrooms has increased dramatically in recent years, due to rapidly changing scientific evidence, public opinion, and regional policies. Although psychedelics remain schedule I substances at the federal level, they are unevenly regulated by a patchwork of state and municipal policies. In addition to decriminalized naturalistic use, a growing number of states are creating legal frameworks for the provision of psychedelic services for adults, for any purpose. These environments differ greatly from rigorous clinical trials, where participants are highly screened and known doses of psychedelics are paired with extensive preparation and psychotherapy. Although clinical trial results for psychiatric conditions are promising, research on the use, safety, and health effects of psychedelics in community settings-where most psychedelic use occurs-remains scant. Understanding real-world trends in psychedelic use is of great public health importance given that the rapid speed at which these policies are changing far outpaces the research, with some analyses projecting over half of US states legalizing psychedelics by 2037. Drawing on our substantial expertise in conducting research focused on how and why people use psychedelics as well as associated health outcomes, our objective is to characterize national perceptions of risks and safety, use patterns, and safety outcomes associated with psychedelics. Our overarching hypotheses are: 1) interest in and use of psychedelics is rising-especially in jurisdictions with active psychedelic decriminalization policies, 2) policy changes will impact use patterns (e.g., at licensed centers VS. Home) and substance sourcing (i.e., illicit VS. Licit), and 3) psychedelic use impacts other drug use, either in polypharmacy or substitution contexts. To test these hypotheses, we propose two aims: 1) conduct four annual waves of a nationally-representative, probability weighted survey (N=5,000 individuals per wave) via the national opinion research center's amerispeak panel to characterize perceptions of harm and safety of psychedelics compared to other drugs, as well as psychedelic use prevalence, and; 2) among individuals reporting past-year psychedelic use in aim 1, we will further assess intention for use, use characteristics (e.g., substance used, use with or without a therapist), health outcomes (e.g., mood disorder symptoms), side effects, and impacts of psychedelic use on other substances. In both aims, we will assess relationships between existing psychedelic policies (e.g., decriminalization) and our findings. In the face of rapidly changing policies and public perception, our study will effectively monitor national trends detailing psychedelic safety in real-world contexts, how these substances are used, and their associated health outcomes, including on mood and substance use. We will directly disseminate our results to patient advocacy groups, clinicians, and policymakers, providing critical evidence to inform appropriate public health outreach and education efforts in the ERA of psychedelic policy reform.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $726,696 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Research Foundation For The State University Of New York | $50,355 | |
| Legacy Emanuel Hospital & Health Center | $60,850 |
Quick answers
Who received award R01DA061818?
R01DA061818 was awarded to Regents Of The University Of Michigan by National Institute on Drug Abuse (National Institutes of Health) on May 25, 2026.
How much is award R01DA061818 worth?
$726,696 has been obligated on R01DA061818.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award